November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators and ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

LAVAL, Quebec, Feb. 25, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the presentation of new long-term, preliminary results from the Phase II ...

SANANTONIO -- San Antonio doctors are hailing a new treatment for prostate cancer. It s not only increasing survival, but it s much easier on patients than traditional chemotherapy.

Dendreon is readying a $5 million-per-quarter “targeted” DTC advertising campaign as the company seeks to goose sluggish growth in sales of its prostate cancer treatment Provenge. Said EVP, global ...

A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval recently, offering an important alternative to more taxing treatments like ...

Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

SEATTLE--(BUSINESS WIRE)-- September 17, 2013 - Dendreon Corporation (NAS: DNDN) today announced that the European Commission (EC) has granted marketing authorization for PROVENGE® (autologous ...

Shares of Dendreon Corp. gained Monday, bucking the broader market, as a Lazard Capital analyst upgraded shares on the sales potential for the prostate cancer drug Provenge. The stock rose $1.35, or 7 ...